Research and Markets: Idiopathic Pulmonary Fibrosis Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l2hrwk/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering.

Idiopathic Pulmonary Fibrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication.

A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India.

The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Key Topics Covered:

1. Indication Overview
2. Marketed Drugs Assessment
3. Marketed Details of Drugs by Application Type
4. Marketed Details of Drugs (NDA) by Marketing Status
5. Marketed Details of Drugs by Patent Expiration Timeline
6. The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
7. The API Manufacturers by the United States Drug Master File (US DMF) Status
8. The API Manufacturers by the US DMF Status (Drug Specific)
9. The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
10. The API Manufacturers by the US DMF Status (Drug Specific)
11. Drugs Market Data and Forecasted Sales Figures (2011-2015)
12. Marketed Drugs Information
13. Drugs Description
14. Route of Synthesis
15. Global Active Pharmaceutical Manufacturers
16. Approval Status
17. Patent and Exclusivity Details
18. Company Overview
19. Phase III Drugs Information
20. Phase III Drugs Description
21. The United States Drug Master Filings (US DMF)
22. Discontinued Drugs Information
    

Companies Mentioned

• Horizon Pharma, Inc.
• UCB, Inc.
• Concordia Pharmaceuticals Inc.

For more information visit http://www.researchandmarkets.com/research/l2hrwk/idiopathic